Shanghai Yinnuo

Yinnuo Pharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of novel treatments for metabolic disorders. The company's core focus is on the incretin pathway, with a robust pipeline of GLP-1 receptor agonists and multi-target agonists. Its lead asset, supaglutide (YN001), is a long-acting humanized GLP-1 analog that has demonstrated promising efficacy and safety in Phase 3 trials for type 2 diabetes. Beyond diabetes, Yinnuo is expanding its portfolio to address obesity and non-alcoholic steatohepatitis (NASH) through dual-agonist and oral delivery technologies. The company is backed by prominent venture capital firms and operates its own GMP-compliant manufacturing facilities.